Shannon Campbell
Vermögen: 19 680 $ am 31.05.2026
Vermögen: 19 680 $ am 31.05.2026
Shannon Campbell is currently Director at Zentalis Pharmaceuticals, Inc. since 2026 and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Formerly, Ms. Campbell was Chief Commercial Officer & Executive VP at Merus NV from 2022 to 2026 and Vice President & General Manager-Oncology at Bayer HealthCare Pharmaceuticals, Inc. from 2005 to 2017.
Education includes undergraduate studies at Ithaca College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.04.2026 | 8’865 ( 0.02% ) | 19 680 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.04.2024 |
| ZENTALIS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 22.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | 01.01.2026 |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Corporate Officer/Principal | 01.01.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Ithaca College
Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen